FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer

ConclusionsOur results suggest a role of FAM83D in NSCLC development. In addition, our results  indicate that NSCLC patients exhibiting FAM83D overexpression are likely to benefit from AKT and/or mTOR inhibitor treatment.

Source: Cellular Oncology - January 30, 2020 Category: Cancer & Oncology Source Type: research